Antibody Drug Conjugate Market Industry Report 2024-2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions - ResearchAndMarkets.com

The "Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions" report has been added to ResearchAndMarkets.com's offering.

The global antibody drug conjugate market is estimated to grow from USD 7.72 billion in the current year to USD 23.3 billion by 2035, at a CAGR of 9.63% during the forecast period, till 2035.

Over the years, various technical developments, such as enhanced pharmacokinetic and pharmacodynamic properties and antibody engineering have paved the way for antibody drug conjugates to be considered as a viable therapeutic modality for the treatment of solid tumors and hematological malignancies. Till date, over 280 antibody drug conjugates have been either approved or being investigated in clinical studies, whereas more than 250 candidates are in the early stages of development. Examples of the USFDA approved drugs include Zynlonta, Akalux, Aidixi.

Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side effects. Till date, several clinical trials have shown the therapeutic superiority (over conventional cancer treatment options) and efficacy of antibody-drug conjugates. Therefore, the rising population of various oncological disorders is one of the key drivers for the antibody drug conjugate market. Driven by the availability of innovative technology platforms, lucrative funding opportunities and encouraging clinical trial results, the antibody drug conjugates market is poised to grow in the long-run, as multiple product candidates are expected to receive marketing approval in the coming decade.

Antibody Drug Conjugate Market Key Insights

The report delves into the current state of the antibody drug conjugate market and identifies potential growth opportunities within the industry. Some key findings from the report include:

• The landscape of ADCs has steadily evolved over the past decade; more than 530 ADC therapy programs are being evaluated by over 140 drug developers, worldwide.
• Currently, 47% of the ADCs are in discovery / preclinical stages of development; of these, close to 160 ADCs utilize auristatin and maytansinoid payloads.
• In order to gain a competitive edge, ADC developers are actively exploring novel targets for the treatment of a wide array of indications.
• Since 2010, 560+ clinical trials have been registered to evaluate the safety and efficacy of various ADCs; majority of these studies have been conducted across various sites in the US.
• Developers have already evaluated more than 190 ADCs in combination with other therapeutic modalities for the treatment of various oncological disorders.
• The growing interest in this field is evident from the rise in partnership activity over the years; in fact, the maximum partnerships, till date, were inked recently.
• Considering the enormous opportunities associated with ADCs for the treatment of cancer, investors have readily extended funds, worth nearly USD 30 billion, in the last decade.
• Several researchers from renowned universities, currently involved in evaluating efficacy and safety of ADCs, have emerged as prominent KOLs.
• Over the years, the intellectual capital related to the therapeutic applications of ADCs has grown at a commendable pace; more than 3,330 patents have been filed by both industry and non-industry players.
• A number of grants, worth over USD 135 million, have been awarded for research activity related to ADCs; nearly 90% of these grants extend a support period of up to 10 years.
• Stakeholders are exploring diverse commercialization strategies across different stages of a drug's launch cycle; for drugs nearing patent expiry, these developers are expected to adopt lifecycle management strategies.
• Presently, around 35 players, across the globe, claim to have the required capabilities to offer contract manufacturing / conjugation services for ADCs; of these, over 10 players claim to be one-stop-shops.
• With a promising developmental pipeline, the global market is anticipated to witness an annualized growth of nearly 10% over the next decade.

Antibody Drug Conjugate Market Research Coverage

• The report features an in-depth analysis of the antibody drug conjugate market, focusing on key market segments, including target disease indication, therapeutic area, linker, payload, target antigens and key geographical regions.
• A comprehensive evaluation of close to 400 antibody drug conjugates / ADC therapeutics that have been either approved or being evaluated in different stages of development. In addition, it includes information on various antibody drug conjugate developers, based on their year of establishment, company size, location of headquarters and most active players.
• A comprehensive competitive analysis of biological targets, examining factors, such as number of antibody drug conjugates being developed against them, number of unique target disease indications and number of companies developing antibody-drug conjugates for the target.
• In-depth profiles of key industry players in antibody drug conjugate market, focusing on company overviews, financial information, product portfolio, recent developments, and an informed future outlook.
• Detailed profiles of marketed ADC therapeutics, focusing on overview of the therapy, its mechanism of action, target antigen, linker, payload, type of therapy and details related to sales generated.
• Examination of completed, ongoing, and planned clinical studies of various drug conjugates.
• An in-depth examination that emphasizes the key opinion leaders (KOLs) within this field includes an evaluation of various principal investigators overseeing clinical trials associated with antibody drug conjugates.
• Detailed analysis of various patents filed / granted related to antibody drug conjugates based on type of patent, patent publication year, patent application year, geographical location, type of players, assigned CPC symbol, type of organization, and leading industry / academic players. It also includes a patent benchmarking analysis and a detailed valuation analysis.
• A comprehensive evaluation of various grants that have been awarded to research institutes engaged in conducting research related to antibody drug conjugates, since 2016, based on various important parameters, such as year of grant award, amount awarded, funding institute center, support period, type of grant application, purpose of grant award, activity code, study section involved, popular NIH departments, prominent program officers, leading recipient organizations and key regions.
• An analysis of the key promotional strategies that have been adopted by the developers of marketed products, namely Adcetris, Besponsa, Enhertu, Kadcyla, Mylotarg, Polivy, and Trodelvy.
• Assessment of the success protocol model for the recently approved ADC therapeutics, based on several relevant parameters, such as dosing frequency, drug efficacy, drug exclusivity, fatality rate, geographical reach, intra-class competition, line of treatment, prevalence, price, type of therapy, and existing competition among developers.
• An overview of various conjugation and linker technologies along with the types that are presently being employed in the designing and development of antibody drug conjugates. In addition, it presents a list of the conjugation and linker technologies that are presently being employed in the designing and development of antibody drug conjugates.
• An overview of research aimed at enhancing the analysis of non-clinical data to support first-in-human (FIH) dose selection for antibody drug conjugates. It also examines the various methods employed to estimate FIH doses. Additionally, it highlights potential FIH starting doses and the estimated dose escalations necessary to achieve the maximum tolerated dose (MTD) in humans.

Antibody Drug Conjugate Market Overview

• No. of ADCs Approved / Under Development across Clinical and Preclinical Stages: 530+
• Amount Invested in this Domain to Date: USD ~30 Billion
• Current Market Size: USD 7.72 Billion
• Market Size in 2035: USD 23.3 Billion
• CAGR: 9.63%

Key Players in the Antibody Drug Conjugates Market

• ADC Therapeutics
• Astellas Pharma
• AstraZeneca
• Byondis
• Daiichi Sankyo
• Genentech
• Gilead Sciences
• ImmunoGen
• Pfizer
• RemeGen

Key Questions Answered in this Report

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What are the factors that are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET OVERVIEW

5. TARGET COMPETITIVENESS ANALYSIS

6. COMPANY AND DRUG PROFILES

• ADC Therapeutics
• Astellas Pharma
• AstraZeneca
• Byondis
• Daiichi Sankyo
• Genentech
• Gilead Sciences
• ImmunoGen
• Pfizer
• RemeGen
• Seagen

7. CLINICAL TRIAL ANALYSIS

8. KEY OPINION LEADERS

9. COMBINATION THERAPIES

10. PARTNERSHIPS AND COLLABORATIONS

11. FUNDING AND INVESTMENT ANALYSIS

12. PATENT ANALYSIS

13. ACADEMIC GRANTS ANALYSIS

14. KEY COMMMERCIALIZATION STRATEGIES

15. PROMOTIONAL ANALYSIS

• Adcetris
• Besponsa
• Enhertu
• Kadcyla
• Mylotarg
• Polivy
• Trodelvy

16. SUCCESS PROTOCOL ANALYSIS

• Adcetris (Seagen / Takeda Oncology)
• Aidixi (RemeGen)
• Akalux (Rakuten Medical)
• Besponsa (Pfizer / UCB)
• Blenrep (GlaxoSmithKline)
• Elahere (ImmunoGen)
• Enhertu (Daiichi Sankyo / AstraZeneca)
• Kadcyla (Genentech / ImmunoGen)
• Padcev (Seagen / Astellas Pharma)
• Polivy (Genentech)
• Tivdak (Seagen / Genmab)
• Trodelvy (Gilead Sciences)
• Zynlonta (ADC Therapeutics)

17. NOVEL CONJUGATION AND LINKER TECHNOLOGY PLATFORMS

18. ASSESSMENT OF NON-CLINICAL DATA FIRST IN HUMAN DOSING

19. COST PRICE ANALYSIS

20. CASE STUDY 1: CONTRACT MANUFACTURING OF ANTIBODY-DRUG CONJUGATES

20.1. Chapter Overview

20.2. Key Steps in Antibody Drug Conjugate Manufacturing Process

20.3. Technical Challenges Related to Antibody Drug Conjugate Manufacturing

20.4. Challenges Associated with Supply Chain and Method Transfer

20.5. Limitations of In-House Manufacturing

20.6. Investments in Antibody Drug Conjugate Manufacturing Capability Expansions

20.7. Collaborations Established for Antibody-Drug Conjugate Manufacturing

20.8. Growing Demand for Antibody-Drug Conjugate Contract Manufacturing

20.9. CMOs with Linker Manufacturing Capabilities

20.10. CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities

20.11. CMOs with Conjugation Capabilities

20.12. Antibody Drug Conjugate One-Stop-Shops

20.13. Increasing Demand for One-Stop-Shops

21. CASE STUDY 2: COMPANION DIAGNOSTICS FOR ANTIBODY DRUG CONJUGATES THERAPEUTICS

21.1. Chapter Overview

21.2. Companion Diagnostics for Antibody Drug Conjugates

21.3. Companion Diagnostics For Antibody Therapeutics

22. SWOT ANALYSIS

23. MARKET FORECAST AND OPPORTUNITY ANALYSIS

Antibody Drug Conjugates Market: Product-wise Sales Forecast to 2035

• Adcetris
• Aidixi
• Besponsa
• Blenrep
• Elahere
• Enhertu
• Kadcyla
• Padcev
• Polivy
• Tivdak
• Trodelvy
• Zynlonta
• Datopotamab Deruxtecan
• Patritumab Deruxtecan
• SHR-A1811
• SKB264
• TAA013
• Telisotuzumab Vedotin
• Trastuzumab Duocarmazine
• Tusamitamab Ravtansine
• Upifitamab Rilsodotin

For more information about this report visit https://www.researchandmarkets.com/r/ite8u5

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241203183899/en/